Tokyo Tape
Sign in
← Tohoku Chemical

Quarterly report · Q3

7446.TEDINET S100RLXQ
Period2022-10-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥26.9bn2022-10-01 → 2023-06-30Cons.Net sales
Revenue¥37.3bn2021-10-01 → 2022-09-30Cons.Net sales (5-year summary)
Revenue¥27.9bn2021-10-01 → 2022-06-30Cons.Net sales
Operating income¥659m2022-10-01 → 2023-06-30Cons.Operating income
Operating income¥763m2021-10-01 → 2022-06-30Cons.Operating income
Ordinary income¥708m2022-10-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥1.0bn2021-10-01 → 2022-09-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥814m2021-10-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥707m2022-10-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥786m2021-10-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥499m2022-10-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥658m2021-10-01 → 2022-09-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥539m2021-10-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥507m2022-10-01 → 2023-06-30Cons.Profit loss
Net income¥559m2021-10-01 → 2022-06-30Cons.Profit loss
Total assets¥17.8bnat 2023-06-30Cons.Assets
Total assets¥17.5bnat 2022-09-30Cons.Assets
Total assets¥15.0bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥10.5bnat 2023-06-30Cons.Liabilities
Total liabilities¥10.8bnat 2022-09-30Cons.Liabilities
Net assets / equity¥7.2bnat 2023-06-30Cons.Net assets
Net assets / equity¥6.7bnat 2022-09-30Cons.Net assets
Net assets / equity¥6.6bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥1.4bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥1.4bnat 2022-09-30Cons.Cash and deposits
EPS (basic)¥553.842022-10-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥146.632023-04-01 → 2023-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥728.762021-10-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥596.992021-10-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥185.032022-04-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio40.3%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio37.7%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio43.2%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Otherother segmentsrevenue2022-10-01 → 2023-06-30¥313m
Otherother segmentsrevenue external2022-10-01 → 2023-06-30¥313m
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue2022-10-01 → 2023-06-30¥2.5bn
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue external2022-10-01 → 2023-06-30¥2.5bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue2022-10-01 → 2023-06-30¥13.5bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2022-10-01 → 2023-06-30¥13.5bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue2022-10-01 → 2023-06-30¥10.6bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2022-10-01 → 2023-06-30¥10.6bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-10-01 → 2023-06-30¥26.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-10-01 → 2023-06-30¥26.9bn
Otherother segmentsrevenue2021-10-01 → 2022-06-30¥318m
Otherother segmentsrevenue external2021-10-01 → 2022-06-30¥318m
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue2021-10-01 → 2022-06-30¥2.4bn
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue external2021-10-01 → 2022-06-30¥2.4bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue2021-10-01 → 2022-06-30¥13.8bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2021-10-01 → 2022-06-30¥13.8bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue2021-10-01 → 2022-06-30¥11.4bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2021-10-01 → 2022-06-30¥11.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-10-01 → 2022-06-30¥27.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-10-01 → 2022-06-30¥27.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 382
ItemContextValueUnit
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member58900
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.061
Number of shares held in own name treasury shares etcCurrentQuarterInstant58900
Number of shares held in others names treasury shares etcCurrentQuarterInstant－
Total number of shares held treasury shares etcCurrentQuarterInstant58900
Shareholding ratio treasury shares etcCurrentQuarterInstant0.061
Cash and depositsPrior1YearInstant1407655000JPY
Cash and depositsCurrentQuarterInstant1367675000JPY
Notes and accounts receivable trade and contract assetsPrior1YearInstant9413890000JPY
Notes and accounts receivable trade and contract assetsCurrentQuarterInstant9282518000JPY
Electronically recorded monetary claims operating caPrior1YearInstant297093000JPY
Electronically recorded monetary claims operating caCurrentQuarterInstant351039000JPY
MerchandisePrior1YearInstant1158309000JPY
MerchandiseCurrentQuarterInstant1131848000JPY
Lease investment assets caPrior1YearInstant123287000JPY
Lease investment assets caCurrentQuarterInstant79268000JPY
Other caPrior1YearInstant311112000JPY
Other caCurrentQuarterInstant307793000JPY
Allowance for doubtful accounts caPrior1YearInstant-1750000JPY
Allowance for doubtful accounts caCurrentQuarterInstant-80000JPY
Current assetsPrior1YearInstant12709597000JPY
Current assetsCurrentQuarterInstant12520063000JPY
Buildings and structures netPrior1YearInstant480710000JPY
Buildings and structures netCurrentQuarterInstant542961000JPY
LandPrior1YearInstant1495006000JPY
LandCurrentQuarterInstant1495006000JPY
Lease assets net ppePrior1YearInstant135870000JPY
Lease assets net ppeCurrentQuarterInstant159249000JPY
Other net ppePrior1YearInstant329887000JPY
Other net ppeCurrentQuarterInstant336853000JPY
Property plant and equipmentPrior1YearInstant2441474000JPY
Property plant and equipmentCurrentQuarterInstant2534070000JPY
SoftwarePrior1YearInstant7677000JPY
SoftwareCurrentQuarterInstant13516000JPY
Software in progressPrior1YearInstant198245000JPY
Software in progressCurrentQuarterInstant314480000JPY
Other iaPrior1YearInstant671000JPY
Other iaCurrentQuarterInstant217000JPY
Intangible assetsPrior1YearInstant206595000JPY
Intangible assetsCurrentQuarterInstant328213000JPY
Investment securitiesPrior1YearInstant1433980000JPY
Investment securitiesCurrentQuarterInstant1671127000JPY
Lease investment assets ioaPrior1YearInstant110231000JPY
Lease investment assets ioaCurrentQuarterInstant78332000JPY
Other ioaPrior1YearInstant643409000JPY
Other ioaCurrentQuarterInstant645468000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-25677000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-21615000JPY
Investments and other assetsPrior1YearInstant2161943000JPY
Investments and other assetsCurrentQuarterInstant2373313000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-09-30pass
balance sheet identityconsolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2023-06-30pass
statement vs summary · revenueconsolidated 2021-10-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-10-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-09-30pass
statement vs summary · total assetsconsolidated 2023-06-30pass